Oracle and Wipro Launched Cloud Pharmacovigilance Service
The partnership allows life sciences firms to outsource drug safety management and avoid maintaining on-premise infrastructure.
Updated on Sept. 22, 2026 in Healthcare
Live Poll
Do you trust that outsourcing essential safety operations to larger technology partners improves product reliability?
Oracle Life Sciences and Wipro have partnered to offer cloud-based pharmacovigilance services using the Oracle Argus platform. This collaboration aims to help organizations manage drug safety data and regulatory reporting without the burden of on-premise systems.
Why it matters
By shifting to a cloud-based service model, companies can accelerate service deployment and scale their pharmacovigilance operations more efficiently. The partnership targets the need for faster implementation timelines across the global drug safety lifecycle.
The partnership leverages the Oracle Argus Business Process Services platform to manage complex drug safety data versus traditional on-premise systems. The initiative focuses on scaling operations across the entire drug safety lifecycle for life sciences organizations.
The players
Oracle Life Sciences
A division of the global technology firm providing enterprise software and cloud solutions for clinical research and pharmaceutical operations.
Wipro
A global information technology and consulting company that provides business process services for the healthcare and life sciences sectors.
The details
Wipro will deploy preconfigured Oracle Argus environments to streamline regulatory reporting, case processing, and post-marketing surveillance for life sciences clients. This managed service approach shifts the technical burden of platform maintenance to the providers, allowing operators to focus on safety data analysis rather than system infrastructure management.
Timeline
September 22, 2026: Oracle and Wipro announced their partnership.
Market Landscape
This partnership follows the industry trend toward offloading complex, data-heavy compliance tasks to specialized third-party cloud service providers. It builds on the existing standard of the Oracle Argus platform to provide a more scalable alternative to traditional on-premise safety systems.
Operators in life sciences should evaluate whether their existing pharmacovigilance systems provide sufficient scalability for current regulatory requirements. Consider whether shifting to a managed cloud environment could reduce IT overhead and improve the speed of regulatory filings.
The takeaway
The move toward managed service platforms highlights the industry effort to move away from legacy on-premise infrastructure in favor of scalable cloud solutions. Evaluate your current pharmacovigilance lifecycle to determine if preconfigured environments could reduce your firm's implementation lag.
Further reading
For broader insights on industry shifts, visit the Healthcare section.
Live Poll
Do you trust that outsourcing essential safety operations to larger technology partners improves product reliability?
